NASDAQ
IMPL

Impel Neuropharma Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Impel Neuropharma Inc Stock Price

Vitals

Today's Low:
$0.41
Today's High:
$0.5879
Open Price:
$0.42
52W Low:
$0.285
52W High:
$7.69
Prev. Close:
$0.41
Volume:
2194746

Company Statistics

Market Cap.:
$10.69 million
Book Value:
-3.333
Revenue TTM:
$19.05 million
Operating Margin TTM:
-412.37%
Gross Profit TTM:
$6.16 million
Profit Margin:
0%
Return on Assets TTM:
-59.41%
Return on Equity TTM:
-2546.09%

Company Profile

Impel Neuropharma Inc had its IPO on 2021-04-23 under the ticker symbol IMPL.

The company operates in the Healthcare sector and Biotechnology industry. Impel Neuropharma Inc has a staff strength of 160 employees.

Stock update

Shares of Impel Neuropharma Inc opened at $0.42 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.41 - $0.59, and closed at $0.55.

This is a +34.59% increase from the previous day's closing price.

A total volume of 2,194,746 shares were traded at the close of the day’s session.

In the last one week, shares of Impel Neuropharma Inc have increased by +22.62%.

Impel Neuropharma Inc's Key Ratios

Impel Neuropharma Inc has a market cap of $10.69 million, indicating a price to book ratio of 18.4568 and a price to sales ratio of 10.3666.

In the last 12-months Impel Neuropharma Inc’s revenue was $19.05 million with a gross profit of $6.16 million and an EBITDA of $-77723000. The EBITDA ratio measures Impel Neuropharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Impel Neuropharma Inc’s operating margin was -412.37% while its return on assets stood at -59.41% with a return of equity of -2546.09%.

In Q2, Impel Neuropharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 134.9%.

Impel Neuropharma Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-3.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Impel Neuropharma Inc’s profitability.

Impel Neuropharma Inc stock is trading at a EV to sales ratio of 6.8434 and a EV to EBITDA ratio of -0.6394. Its price to sales ratio in the trailing 12-months stood at 10.3666.

Impel Neuropharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$44.81 million
Total Liabilities
$121.22 million
Operating Cash Flow
$0
Capital Expenditure
$132000
Dividend Payout Ratio
0%

Impel Neuropharma Inc ended 2024 with $44.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $44.81 million while shareholder equity stood at $-79158000.00.

Impel Neuropharma Inc ended 2024 with $0 in deferred long-term liabilities, $121.22 million in other current liabilities, 24000.00 in common stock, $-358534000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $15.16 million and cash and short-term investments were $15.16 million. The company’s total short-term debt was $49,551,000 while long-term debt stood at $0.

Impel Neuropharma Inc’s total current assets stands at $32.90 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $6.81 million compared to accounts payable of $3.46 million and inventory worth $6.99 million.

In 2024, Impel Neuropharma Inc's operating cash flow was $0 while its capital expenditure stood at $132000.

Comparatively, Impel Neuropharma Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.55
52-Week High
$7.69
52-Week Low
$0.285
Analyst Target Price
$40

Impel Neuropharma Inc stock is currently trading at $0.55 per share. It touched a 52-week high of $7.69 and a 52-week low of $7.69. Analysts tracking the stock have a 12-month average target price of $40.

Its 50-day moving average was $1.06 and 200-day moving average was $1.88 The short ratio stood at 8.42 indicating a short percent outstanding of 0%.

Around 108.2% of the company’s stock are held by insiders while 7461.1% are held by institutions.

Frequently Asked Questions About Impel Neuropharma Inc

The stock symbol (also called stock or share ticker) of Impel Neuropharma Inc is IMPL

The IPO of Impel Neuropharma Inc took place on 2021-04-23

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$1.32
0
0%
$16.3
-0.33
-1.98%
PetroTal Corp (PTALF)
$0.57
0.01
+1.59%
$1.03
-0.02
-1.9%
Teladoc Inc (TDOC)
$22.46
-0.33
-1.45%
$665.9
-42.7
-6.03%
$321.45
-13.45
-4.02%
$48.26
-1.78
-3.56%
$4
0.03
+0.76%
$143.65
-7.35
-4.87%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

Address

201 Elliott Avenue West, Seattle, WA, United States, 98119